Interest in anti-inflammatory IRAK4 signaling is ramping up, as small-molecule ‘degraders’ that bind both the kinase and E3 ubiquitin ligases prepare to take on traditional kinase inhibitors.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Signal Transduction and Targeted Therapy Open Access 09 June 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mullard, A. IRAK4 degrader to take on innate immunity. Nat Biotechnol 38, 1221–1223 (2020). https://doi.org/10.1038/s41587-020-0724-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-020-0724-8
This article is cited by
-
Protein kinases: drug targets for immunological disorders
Nature Reviews Immunology (2023)
-
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Signal Transduction and Targeted Therapy (2022)